Published in Medical Letter on the CDC and FDA, February 14th, 2000
The study, a Phase I clinical trial sponsored by Enzo Therapeutics, is being conducted at the University of California in San Francisco and is viewed as a critical step forward in the company's development of a gene medicine for the treatment of HIV-1 infection.
Dean Engelhardt, PhD, Enzo, presenting at the 7th Retroviruses and Opportunistic Infections Conference in San Francisco, reported that engineered cells have now been observed in circulation for a period exceeding 4 months. Furthermore, he said that these engineered cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA